MaxCyte Stock (NASDAQ:MXCT)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.25

52W Range

$2.00 - $5.20

50D Avg

$2.22

200D Avg

$3.26

Market Cap

$240.28M

Avg Vol (3M)

$876.94K

Beta

0.25

Div Yield

-

MXCT Company Profile


MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

114

IPO Date

Jul 30, 2021

Website

MXCT Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
Product$21.09M--
Product and Service, Other$1.13M--
Product sales-$18.60M$27.73M
Other-$897.00K$1.02M

Fiscal year ends in Dec 24 | Currency in USD

MXCT Financial Summary


Dec 24Dec 23Dec 22
Revenue$38.63M$41.29M$44.26M
Operating Income$-47.05M$-48.30M$-27.36M
Net Income$-41.05M$-37.92M$-19.78M
EBITDA$-42.91M$-44.13M$-20.87M
Basic EPS$-0.39$-0.37$-0.19
Diluted EPS$-0.39$-0.37$-0.19

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25May 10, 25 | 4:30 PM
Q4 24Mar 11, 25 | 6:08 PM
Q3 24Nov 06, 24 | 4:30 PM

Peer Comparison


TickerCompany
IPSCCentury Therapeutics, Inc.
LUNGPulmonx Corporation
KIDSOrthoPediatrics Corp.
CTKBCytek Biosciences, Inc.
GLUEMonte Rosa Therapeutics, Inc.
NUVLNuvalent, Inc.
CRBUCaribou Biosciences, Inc.